(VIANEWS) – LNA SANTE (LNA.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| LNA SANTE (LNA.PA) | €20.30 | 2.54% | 9.08% |
| ESSILORLUXOTTICA (EL.PA) | €180.14 | 1.78% | 6.44% |
| LUMIBIRD (LBIRD.PA) | €12.06 | 1.25% | 5.68% |
| VIRBAC (VIRP.PA) | €356.00 | 0.49% | 13.8% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. LNA SANTE (LNA.PA)
2.54% Forward Dividend Yield and 9.08% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.9. Meaning, the purchaser of the share is investing €8.9 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LNA SANTE’s stock is considered to be oversold (<=20).
More news about LNA SANTE.
2. ESSILORLUXOTTICA (EL.PA)
1.78% Forward Dividend Yield and 6.44% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €5.21.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 34.58. Meaning, the purchaser of the share is investing €34.58 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.44%.
More news about ESSILORLUXOTTICA.
3. LUMIBIRD (LBIRD.PA)
1.25% Forward Dividend Yield and 5.68% Return On Equity
Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two segments, Photonics and Medical. The company offers solid-state and diode lasers, fiber lasers, fiber lasers/amplifiers and components, Laser rangefinder and LiDAR wind doppler LiDAR, medical and ophthalmological equipment. Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. The company was incorporated in 1970 and is headquartered in Lannion, France.
Earnings Per Share
As for profitability, LUMIBIRD has a trailing twelve months EPS of €0.45.
PE Ratio
LUMIBIRD has a trailing twelve months price to earnings ratio of 26.8. Meaning, the purchaser of the share is investing €26.8 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.68%.
Volatility
LUMIBIRD’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.75%, a negative 0.51%, and a positive 1.71%.
LUMIBIRD’s highest amplitude of average volatility was 0.75% (last week), 2.76% (last month), and 1.71% (last quarter).
More news about LUMIBIRD.
4. VIRBAC (VIRP.PA)
0.49% Forward Dividend Yield and 13.8% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.13.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 25.19. Meaning, the purchaser of the share is investing €25.19 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.8%.
Yearly Top and Bottom Value
VIRBAC’s stock is valued at €356.00 at 16:30 EST, way higher than its 52-week high of €314.00.
More news about VIRBAC.
